Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients

References

• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567. doi:10.1002/ajh.25791
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021;32(3):309–322. doi:10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Kumar S, Callander N, Adekola K, et al. Multiple Myeloma, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;28(12):1685–1717. doi:10.6004/jnccn.2020.0057
   Web of Science ®Google Scholar
• Nijhof IS, van de Donk NWCJ, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19–37. doi:10.1007/s40265-017-0841-y
   PubMed Web of Science ®Google Scholar
• Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22(22):5419–5427. doi:10.1158/1078-0432.CCR-16-0625
   PubMed Web of Science ®Google Scholar
• Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematol Am Soc Hematol Educ Progr. 2017;2017(1):508. doi:10.1182/ASHEDUCATION-2017.1.508
   PubMed Web of Science ®Google Scholar
• Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell. 2012;23(18):3673–3676. doi:10.1091/mbc.E12-01-0045
   PubMed Web of Science ®Google Scholar
• Camus V, Miloudi H, Taly A, Sola B, Jardin F. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol. 2017;10(1). doi:10.1186/s13045-017-0412-4
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Senapedis W, Baloglu E, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(5):335–345. doi:10.1016/j.clml.2018.03.003
   PubMed Web of Science ®Google Scholar
• Azizian NG, Li Y. XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol. 2020;13(1):1–9. doi:10.1186/s13045-020-00903-4
   PubMed Web of Science ®Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738. doi:10.1056/NEJMoa1903455
   PubMed Web of Science ®Google Scholar
• Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7(1). doi:10.1186/s13045-014-0085-1
   Web of Science ®Google Scholar
• Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155–165. doi:10.1038/leu.2013.115
   PubMed Web of Science ®Google Scholar
• Chanukuppa V, Paul D, Taunk K, et al. XPO1 is a critical player for bortezomib resistance in multiple myeloma: a quantitative proteomic approach. J Proteomics. 2019;209:103504. doi:10.1016/j.jprot.2019.103504
   PubMed Web of Science ®Google Scholar
• Bhutani M, Zhang Q, Friend R, et al. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Lancet Haematol. 2017;4(9):e443–e451. doi:10.1016/S2352-3026(17)30143-6
   PubMed Web of Science ®Google Scholar
• Jardin F, Pujals A, Pelletier L, et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am J Hematol. 2016;91(9):923–930. doi:10.1002/ajh.24451
   PubMed Web of Science ®Google Scholar
• Golomb L, Bublik DR, Wilder S, et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell. 2012;45(2):222–232. doi:10.1016/j.molcel.2011.11.022
   PubMed Web of Science ®Google Scholar
• Schmidt J, Braggio E, Kortuem KM, et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013;27(12):2357–2365. doi:10.1038/leu.2013.172
   PubMed Web of Science ®Google Scholar
• Turner JG, Kashyap T, Dawson JL, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016;7(48):78896–78909. doi:10.18632/oncotarget.12969
   PubMedGoogle Scholar
• Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, Phase 3 trial. Lancet. 2020;396(10262):1563–1573. doi:10.1016/S0140-6736(20)32292-3
   PubMed Web of Science ®Google Scholar
• XPOVIO (Karyopharm Therapeutics Inc.): FDA package insert. Available from: https://medlibrary.org/lib/rx/meds/xpovio-1/. Accessed February 1, 2021.
   Google Scholar
• Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, Phase 2 trial. Lancet Haematol. 2020;7(7):e511–e522. doi:10.1016/S2352-3026(20)30120-4
   PubMed Web of Science ®Google Scholar
• Mikhael J, Noonan KR, Faiman B, et al. Consensus recommendations for the clinical management of patients with multiple myeloma treated with selinexor. Clin Lymphoma Myeloma Leuk. 2020;20(6):351–357. doi:10.1016/j.clml.2019.12.026
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Chari A, Chen C, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020;34(9):2430–2440. doi:10.1038/s41375-020-0756-6
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. doi:10.1016/S1470-2045(16)30206-6
   PubMed Web of Science ®Google Scholar
• Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) V5.0; 2017.
   Google Scholar
• Kashyap T, Argueta C, Unger T, et al. Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents. Oncotarget. 2018;9(56):30773–30786. doi:10.18632/oncotarget.25637
   PubMedGoogle Scholar
• Magen H, Geva M, Volchik Y, Avigdor A, Nagler A. Selinexor, bortezomib, and dexamethasone for heavily pretreated multiple myeloma: a case Series. Clin Lymphoma Myeloma Leuk. 2020;20(12):e947–e955. doi:10.1016/j.clml.2020.07.016
   PubMed Web of Science ®Google Scholar
• Mouhieddine TH, Parekh S, Cho HJ, et al. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. Ann Hematol. 2021;100(12):3057–3060. doi:10.1007/s00277-020-04293-y
   PubMed Web of Science ®Google Scholar
• Nexpovio-Union Register of medicinal products - Public health - European Commission. Available from: https://ec.europa.eu/health/documents/community-register/html/h1537.htm. Accessed May 20, 2021.
   Google Scholar
• White DJ, Lentzsch S, Gasparetto C, et al. Safety and efficacy of the combination of selinexor, lenalidomide and dexamethasone (SRd) in Patients with newly diagnosed multiple myeloma. Blood. 2019;134(Supplement_1):3165. doi:10.1182/blood-2019-124370
   Web of Science ®Google Scholar
• Chen CI, Bahlis N, Gasparetto C, et al. Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(Supplement_1):141. doi:10.1182/BLOOD-2019-122907
   Web of Science ®Google Scholar
• Gasparetto C, Lentzsch S, Schiller GJ, et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). J Clin Oncol. 2020;38(15_suppl):8510. doi:10.1200/jco.2020.38.15_suppl.8510
   Web of Science ®Google Scholar